COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study to Evaluate Efficacy and Safety of Oxycodone/Naloxone Compared to OxyContin in Korean Cancer Patients (TOP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01313780
Recruitment Status : Completed
First Posted : March 14, 2011
Results First Posted : October 27, 2016
Last Update Posted : December 22, 2017
Information provided by (Responsible Party):
Mundipharma Korea Ltd

Brief Summary:


To prove non-inferiority of Targin compared to Oxycontin in terms of change of pain intensity

  1. Primary objective: Change of pain intensity (NRS 0-10) score (average pain over 24 hours obtained each evening) within 4 weeks
  2. Secondary objectives: Bowel Habit (worsening/no change/improving), Total dose and frequency of rescue medication, Quality of Life (QOL; EORTC QLQ-C30), Duration to need of laxative use and Adverse events

Condition or disease Intervention/treatment Phase
Cancer Drug: Oxycodone/Naloxone Drug: Oxycodone(single compound) Phase 4

Detailed Description:
This will be a 4-week multicentre, randomized, open label, parallel group, active control study to evaluate efficacy and safety of Targin in comparison with Oxycontin in Korean patients with cancer pain who are administered weak opioid or naïve patients including patient not on the long term strong opioid medication within 3 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 128 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A 4-week Multicentre, Randomized, Open Label, Parallel Group, Active Control Phase IV Study to Evaluate Efficacy and Safety of Oxycodone/Naloxone in Comparison With Oxycontin in Korean Patients With Cancer Pain(TOP)
Study Start Date : May 2011
Actual Primary Completion Date : October 2013
Actual Study Completion Date : June 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 'Oxycodone/Naloxone'
Trade name is Targin(fixed combination drug).
Drug: Oxycodone/Naloxone
Dose and administration : Upto 40mg B.I.D per daily.
Other Name: Targin(fixed combination drug)

Active Comparator: Oxycodone
Trade name is Oxycontin(single compound).
Drug: Oxycodone(single compound)
Dose and administration : Upto 40mg B.I.D per daily.
Other Name: Oxycontin

Primary Outcome Measures :
  1. Change of Pain Intensity From Baseline(visit1) to 4weeks.(visit3) [ Time Frame: 4weeks ]
    Change of pain intensity from 0(No pain) to 10(worst pain imaginable) after 4 weeks treatment .

Secondary Outcome Measures :
  1. Change in Bowel Habits. [ Time Frame: 4 weeks ]
    The change of bowel habits from baseline (Visit 1) in bowel habits at Week 4 was investigated, and was categorized as 'improved', 'unchanged', and 'worsened'.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female cancer patients 20 years of age or older
  2. Cancer related pain that requires treatment with continuous around-the-clock strong opioid analgesic
  3. Moderate to severe pain intensity(NRS pain score 4)
  4. Opioid naïve patients or patients not treated with strong opioids(except PRN) within 4 weeks or patients who has been on weak opioids
  5. Subject who provide signed and dated written voluntary informed consent

Exclusion Criteria:

  1. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant. UNLESS they are:

    • women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner
    • women shoes partners have been sterilized by vasectomy or other means
    • two birth control methods. The two methods can be a double barrier method or a barrier method plus a hormonal method. Adequate barrier methods of contraception include: diaphragm, condom (by the partner), intrauterine device (copper or hormonal), sponge or spermicide. Hormonal contraceptives include any marketed contraceptive agent that includes an estrogen and/or a progestational agent.
  2. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive urine pregnancy test.
  3. Have previously received treatment with Targin or Oxycontin within 4weeks(28days) of screening periods(including PRN)
  4. If subjects started first cycle of chemotherapy during the 2 weeks before the screening visit or during the study, they should be excluded from the study.

    And If the chemotherapy regimen or dosage to be planned to change during the study, the subjects should be excluded from the study.

  5. Patient who is administered laxatives with stable dose for more than 1 week
  6. Patient with evidence of significant structural/functional abnormalities of GI tract which is not appropriate for oral medicine administration. Any history of hypersensitivity to Oxycodone and Naloxone
  7. Patients with significant respiratory depression
  8. Patients with acute or severe bronchial asthma or hypercarbia
  9. Any patient who has or is suspected of having paralytic ileus
  10. Severe Chronic obstructive pulmonary disease, pulmonary heart disease
  11. Targin product contains lactose. Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take
  12. Patients with moderate and severe hepatic impairment
  13. Abnormal aspartate aminotransferase (AST; SGOT), alanine aminotransferase (ALT; SGPT), or alkaline phosphatase levels (>2.5 times the upper limit of normal, it is allowed >5 times the upper limit of normal in case of transition in liver) or an abnormal total bilirubin and/or creatinine level(s) (greater than 1.5 times the upper limit of normal)
  14. Any situation where opioids are contraindicated
  15. Major surgery within 1 month prior to screening or planned surgery
  16. Mainly pain originated other than cancer or cancer related conditions (eg. Musculoskeletal pain, inflammatory pain, diabetic polyneuropathy)
  17. Patients with known or suspected unstable brain metastases or spinal cord compression that may require changes in steroid treatment throughout the duration of the study
  18. Patients with uncontrolled seizures
  19. Requiring interventional treatment for pain such as neurodestructive procedure or regional infusion
  20. With a history of alcohol abuse within 6 months of screening
  21. With a history of illicit drug abuse within 6 months of screening
  22. Patients with increased intracranial pressure
  23. In the investigator's opinion, subjects who are receiving hypnotics or other central nervous system (CNS) depressants that may pose a risk of additional CNS depression with opioid study medication
  24. Patients with myxoedema, not adequately treated hypothyroidism or Addison's disease
  25. Patients receiving opioid substitution therapy for opioid addiction (e.g. methadone or buprenorphine)
  26. Patients with evidence of clinically significant gastrointestinal disease (e.g. paralytic ileus, peritoneal carcinosis), significant structural abnormalities of the gastrointestinal tract (e.g. scarring, obstruction etc) either related or not related to the underlying cancer or disease progression
  27. Patients suffering from diarrhea and/or opioid withdrawal
  28. With a disability that may prevent the patient from completing all study requirements and in particular, interfere with 24hrs pain intensity score
  29. Clinically significant impairment of cardiovascular, respiratory and renal function
  30. Patient who needs acute dose titration or whose pain intensity fluctuate significantly in a short period according to investigator's judgment
  31. Having used other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01313780

Layout table for location information
Korea, Republic of
Seoul, Pungnap-dong, Korea, Republic of, 138-736
Sponsors and Collaborators
Mundipharma Korea Ltd
Layout table for investigator information
Principal Investigator: Kim, M.D Asan Medical Center
Principal Investigator: Ahn, M.D Samsung Medical Center
Principal Investigator: Kim, M.D National Cancer Center
Principal Investigator: Kim, M.D SMG-SNU Boramae Medical Center
Principal Investigator: Lee, M.D Shinchone Yonsei Severance Medical Center
Principal Investigator: Kang Jugnhoon Kyungsang University Hospital
Principal Investigator: Lee Kyunghee, MD Youngnam Univ. Hospital
Principal Investigator: Yoon Hwanjung, MD Chungnam University Hospital
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Mundipharma Korea Ltd Identifier: NCT01313780    
Other Study ID Numbers: OXN10-KR-002
First Posted: March 14, 2011    Key Record Dates
Results First Posted: October 27, 2016
Last Update Posted: December 22, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Mundipharma Korea Ltd:
cancer related pain
Additional relevant MeSH terms:
Layout table for MeSH terms
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists